News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Abeona Therapeutics experienced a 14% stock drop after reporting Q2 revenues that missed analyst expectations, despite treating five Zevaskyn patients. The company faces operational challenges in Zevaskyn's rollout, but management anticipates improvement with experience. Despite these early commercial hurdles, the article assigns a "risk-on …
Abeona Therapeutics reported Q2 2026 net ZEVASKYN revenue of $11.4 million, missing analyst forecasts of $12.24 million, leading to a 10.99% drop in premarket trading. Despite a 31% sequential revenue increase, operational complexities, including manufacturing issues and patient cancellations, impacted recognized sales. The company …
ABEONA THERAPEUTICS INC. reported Q2 2026 financial results, with revenue of $11.38M driven by the first commercial sales of ZEVASKYN after its FDA approval in April 2025. The company posted a net loss of $20.19M and a diluted loss per share of $(0.35), contrasting …
Abeona Therapeutics Inc. announced its financial results for Q2 2026, reporting a 31% quarter-over-quarter increase in ZEVASKYN® revenue to $11.4 million. The company has treated 12 patients with ZEVASKYN since launch and is expanding its qualified treatment center network to enhance patient access. Abeona …
Abeona Therapeutics (ABEO) reported a 31% increase in Q2 2026 net ZEVASKYN revenue, reaching $11.4 million. Despite the revenue growth, the company posted a net loss of $20.2 million. The article also details recent insider selling activity and institutional investor movements in ABEO stock.
Abeona Therapeutics announced its Q2 2026 financial results, reporting $11.4 million in net ZEVASKYN product revenue and a net loss of $20.2 million. The company highlighted ongoing commercial progress for ZEVASKYN, including five patient treatments in Q2 and expansion of its qualified treatment center …
Abeona Therapeutics, Inc. (NASDAQ: ABEO) has secured the FY2027 CMS NTAP for its drug ZEVASKYN, which will enable supplemental Medicare inpatient reimbursement. The company is also preparing to release its Q2 2026 financial results and will host an earnings call on August 13th, 2026, …
Abeona Therapeutics Inc. (Nasdaq: ABEO) will host a conference call on Thursday, August 13, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide a corporate update. The company plans to release its financial results via a press release …
Abeona Therapeutics (Nasdaq: ABEO) will host a conference call on August 13, 2026, at 8:30 a.m. ET to discuss its second-quarter 2026 financial results and provide a corporate update. Financial results will be released in a press release before the call, which will be …
This article analyzes the technical signals for Abeona Therapeutics Inc. (NASDAQ: ABEO), highlighting a breakout underway and no resistance levels above the current price. It presents institutional trading strategies generated by AI models, including position trading, momentum breakout, and risk hedging, along with a …
Abeona Therapeutics Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN® (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule. This designation is expected to enhance Medicare …
Abeona Therapeutics announced that its gene therapy, ZEVASKYN, has received New Technology Add-On Payment (NTAP) status from the Centers for Medicare & Medicaid Services (CMS). This designation provides supplemental reimbursement for ZEVASKYN under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule, …
Abeona Therapeutics has granted equity awards to two new non-executive employees as a material inducement for their employment. The awards consist of up to 10,800 restricted common shares, vesting in three equal annual installments over three years, contingent on continued employment. This action was …
Abeona Therapeutics Inc. announced equity awards for two new non-executive employees, granted under Nasdaq Listing Rule 5635(c)(4). These awards, totaling up to 10,800 restricted shares, will vest over three years, subject to continued employment. Abeona is a biopharmaceutical company focused on cell and gene …
Abeona Therapeutics Inc (ABEO) currently holds an institutional shareholding score of 7.00, placing it 50th out of 155 in the Pharmaceuticals industry. The institutional shareholding proportion is 70.85%, experiencing a 10.33% decrease quarter-over-quarter. James Simons is identified as the largest institutional shareholder, though his …
Abeona Therapeutics Inc (ABEO) has a current financial score of 8.78, placing it 29th out of 155 companies in the Pharmaceuticals industry, indicating stable financial status and high operating efficiency. The company's financial health and operational efficiency scores are strong, with growth potential rated …
Abeona Therapeutics Inc. (ABEO) has a TradingKey Stock Score indicating healthy fundamentals and high growth potential, with its valuation deemed fairly valued within the Pharmaceuticals industry. Analysts have rated it a Strong Buy with a target price of 19.71 USD. The company is actively …
The article provides a valuation analysis for Abeona Therapeutics Inc (ABEO), noting its current valuation score of 7.61, which ranks 123 out of 155 in the Pharmaceuticals industry. It highlights the company's current P/E ratio of 4.77, indicating it is significantly below its recent …
Purcell & Lefkowitz LLP is investigating Abeona Therapeutics Inc. to determine if its directors breached their fiduciary duties, potentially harming shareholders. The investigation focuses on recent corporate actions and could impact shareholder rights and company governance. Shareholders are encouraged to contact the law firm …
Purcell & Lefkowitz LLP has announced a shareholder investigation into Abeona Therapeutics Inc. (NASDAQ: ABEO). The investigation aims to determine if Abeona Therapeutics's directors breached their fiduciary duties through recent corporate actions. Shareholders are encouraged to contact the law firm for more information on …
This article provides a detailed quarterly and annual cash flow statement for Abeona Therapeutics Inc (ABEO), including operating, investing, and financing cash flows, along with related metrics. It aims to help users evaluate the financial health and stability of the company. The data covers …
This article provides an overview of Abeona Therapeutics Inc (ABEO)'s dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years. However, it details multiple stock splits that occurred on July 1, 2022, all categorized …
This article details the shareholder structure of Abeona Therapeutics Inc (ABEO), listing major individual and institutional holders. It breaks down shareholders by type, such as hedge funds and investment advisors, and provides a historical view of institutional shareholdings and recent shareholder activity. The article …
This article provides a detailed analysis of Abeona Therapeutics Inc. (ABEO) using AI models to identify risk zones and trading opportunities. It highlights conflicting market sentiment, an exceptional risk-reward short setup, and offers distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for various …
Abeona Therapeutics' CFO, Joseph Walter Vazzano, reported that 1,478 shares of common stock were withheld to cover tax obligations related to restricted stock awards. The shares were valued at $6.53 each, and after this transaction, he directly holds 492,079 shares. This was a tax-related …
This article highlights top US growth companies with significant insider ownership, which often signals strong internal confidence and alignment with shareholder interests. Despite a recent market dip, these companies, including Abeona Therapeutics, Pagaya Technologies, and York Space Systems, are projected to show substantial annual …
Search by ticker symbol or company name and select a result to open its chart.